These results suggest that the co-treatment of apoA-I and CIGB-258 ameliorated the acute inflammatory response induced by the exposure of CML in a dose-dependent manner of CIGB-258. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.